A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma

The reason for this study is to see if the study drug LY3295668 erbumine is safe in
participants with relapsed/refractory neuroblastoma.

Inclusion Criteria:

- Participants must have relapsed/refractory neuroblastoma and have active disease in
at least one site: bone, bone marrow or soft tissue. Participants must be able to
submit an archival sample of tissue.

- Participants must be able to swallow capsules.

Exclusion Criteria:

- Participants must not have had an allogeneic hematopoietic stem cell, bone marrow,
or solid organ transplant.

- Participants must not have untreated tumor that has spread to the brain or spinal
cord.

- Participants must not have a serious active disease other than neuroblastoma.

- Participants must not have a condition affecting absorption.

- Participants must not have had prior aurora kinase inhibitor exposure.

- Participants must not have a known allergy to the study treatment.

- Participants must not have symptomatic human immunodeficiency virus (HIV) infection
or symptomatic activated/reactivated hepatitis A, B, or C.